HIV Infection as a Model of Accelerated Immunosenescence

Appay, Victor; Sauce, Delphine; Kelleher, Anthony D.

doi:10.1007/978-3-319-64597-1_50-1

Cited by 2 publications

(1 citation statement)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, biomarkers of microbial translocation were not measured in our study. Third, cytomegalovirus and Epstein-Barr virus [18,36]; bacteria and parasites [37,38]; known for their independent associations with chronic immune activation, were not measured. Furthermore, assessment and management of these co-infections was up to the sites and was not part of the formal SECOND-LINE study protocol.…”

Section: Limitationsmentioning

confidence: 99%

Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failure

Mwasakifwa

Amin

Kelleher

et al. 2021

Aids

View full text Add to dashboard Cite

Introduction:We explored associations of inflammatory and immune activation biomarkers at baseline and percentage gain in peripheral and trunk fat and lean mass over 96 weeks in patients with confirmed virological failure initiating lopinaviranchored second-line antiretroviral therapy (ART) regimens. Method:We measured baseline plasma concentration of interleukin (IL)-6, tumour necrosis factor (TNF), neopterin, IL-6, high-sensitivity C-reactive protein (hs-CRP), Ddimer, soluble cluster of differentiation 14 (sCD14), and soluble CD163 in 123 participants of the SECOND-LINE body composition substudy. Linear regression assessed the association between biomarkers and percentage gain in limb/trunk fat and lean mass, adjusting for age, nucleoside or nucleotide reverse transcriptase inhibitor (N(t)RTI) use, body mass index, ethnicity, smoking, viral load, CD4 þ T-cell counts, smoking, duration of ART use, and cholesterol.Results: Mean (standard deviation) age was 38 (7.3) years, CD4 þ T-cell count was 252 (185.9) cells/ml, human immunodeficiency virus viral load was 4.2 (0.9) log 10 copies/ ml, 47% (58/123) were in the N(t)RTI arm (vs. raltegravir [RAL] arm in 53%); 56.1% (69/ 123) were females. In adjusted analyses, for every log 10 increase in baseline levels of IL-6, neopterin, and D-dimer, the percentage gain in peripheral fat over 96 weeks was 11.8% (95% confidence interval [CI]: 0.9-22.6, P ¼ 0.033); neopterin, 11.2% (95% CI: 3.2-19.2, P ¼ 0.007); D-dimer 9.6% (95% CI: 3.1-15.9, P ¼ 0.004), respectively. The associations remained significant when analysis was stratified by N(t)RTI vs. RAL and included only patients with viral suppression at week 48. A significant gradient in lean mass gain was seen across quartiles of IL-6, TNF, neopterin, hsCRP, D-dimer, and sCD14. Conclusion:Inflammatory biomarkers provide important mechanistic insights into the pathogenesis of limb fat and lean mass changes independently of ART.

show abstract

Section: Limitationsmentioning

confidence: 99%